BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36106337)

  • 1. SARS-CoV-2 neutralizing antibody response after three doses of mRNA1273 vaccine and COVID-19 in hemodialysis patients.
    Wang X; Han M; Fuentes LR; Thwin O; Grobe N; Wang K; Wang Y; Kotanko P
    Front Nephrol; 2022; 2():. PubMed ID: 36106337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
    Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
    Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals.
    Park JS; Jeon J; Um J; Choi YY; Kim MK; Lee KS; Sung HK; Jang HC; Chin B; Kim CK; Oh MD; Lee CS
    Infect Chemother; 2024 Mar; 56(1):25-36. PubMed ID: 38014726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
    Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants.
    Cheng HL; Lim SM; Jia H; Chen MW; Ng SY; Gao X; Somani J; Sengupta S; Tay DMY; Chua PWL; R A; Ling SYH; McBee ME; Young BE; Sikes HD; Preiser PR
    Microbiol Spectr; 2022 Oct; 10(5):e0225722. PubMed ID: 36069616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines.
    Wang J; Huang L; Guo N; Yao YP; Zhang C; Xu R; Jiao YM; Li YQ; Song YR; Wang FS; Fan X
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Response to Third and Fourth COVID-19 Vaccination in Hemodialysis Patients and Kidney Transplant Recipients.
    Affeldt P; Koehler FC; Brensing KA; Gies M; Platen E; Adam V; Butt L; Grundmann F; Heger E; Hinrichs S; Kalisch N; Oehm S; Steger G; Wirtz M; Benzing T; Stippel D; Klein F; Kurschat C; Müller RU; Di Cristanziano V
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age and prior vaccination determine the antibody level in children with primary SARS-CoV-2 Omicron infection.
    Huang PC; Lin TY; Chen CC; Wang SW; Tsai BY; Tsai PJ; Tu YF; Ko WC; Cheng CM; Shieh CC; Liu CC; Shen CF;
    J Microbiol Immunol Infect; 2023 Dec; 56(6):1187-1197. PubMed ID: 37739902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
    Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
    Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of SARS-CoV-2 neutralizing antibodies in Omicron breakthrough cases with inactivated vaccination: Role in inferring the history and duration of infection.
    Simayi A; Li C; Chen C; Wang Y; Dong C; Tian H; Kong X; Zhou L; Peng J; Zhang S; Zhu F; Hu J; Xu K; Jin H; Fan H; Bao C; Zhu L
    Front Immunol; 2023; 14():1083523. PubMed ID: 36761738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster.
    Peng P; Feng C; Hu J; He C; Deng H; Fan Q; Xiang J; Tang G; Jiang ML; Hu F; Li F; Wang K; Tang N; Tang XP; Huang A
    iScience; 2022 Nov; 25(11):105465. PubMed ID: 36338432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients.
    Zhang H; Jia Y; Ji Y; Cong X; Liu Y; Yang R; Kong X; Shi Y; Zhu L; Wang Z; Wang W; Fei R; Liu F; Lu F; Chen H; Rao H
    Front Microbiol; 2022; 13():816778. PubMed ID: 35359732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multivariant Surrogate Virus Neutralization Test Demonstrates Distinct SARS-CoV-2-Specific Antibody Responses in People Living with HIV after a Fourth Monovalent mRNA Vaccination or an Omicron Breakthrough Infection.
    Springer DN; Daller S; Knappik M; Prüger K; Hartl S; Breyer-Kohansal R; Puchhammer-Stöckl E; Aberle JH; Weseslindtner L; Breyer MK
    Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.
    Benning L; Klein K; Morath C; Bartenschlager M; Kim H; Buylaert M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Schaier M; Speer C
    Front Immunol; 2022; 13():840136. PubMed ID: 35309320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.
    Takheaw N; Liwsrisakun C; Chaiwong W; Laopajon W; Pata S; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
    Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels and durability of neutralizing antibodies against SARS-CoV-2 Omicron and other variants after ChAdOx-1 or BNT162b2 booster in CoronaVac-primed elderly individuals.
    Takheaw N; Liwsrisakun C; Laopajon W; Pata S; Chaiwong W; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
    Heliyon; 2023 Apr; 9(4):e15653. PubMed ID: 37095993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants.
    Lv Q; Zhou S; Qi F; Zhang Y; Li F; Liu M; Bao L
    Animal Model Exp Med; 2022 Feb; 5(1):89-93. PubMed ID: 35213787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.